登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002194 证券简称：武汉凡谷 公告编号：2025-036 武汉凡谷电子技术股份有限公司 第八届董事会第十三次（临时）会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 一、董事会会议召开情况 武汉凡谷电子技术股份有限公司（以下简称"公司"）第八届董事会第十三次（临时）会议于2025年9月 22日以电子邮件方式发出会议通知，于2025年9月25日上午9:30在武汉市江夏区藏龙岛科技园九凤街5号 公司4号楼3楼1号会议室以现场结合通讯方式召开。应参加本次会议的董事9名，实际参加会议的董事9 名（其中董事兼副总经理贾雄杰先生以通讯的方式参加本次会议），公司全体高级管理人员列席了会 议，会议由董事长孟凡博先生主持。会议召开程序符合《中华人民共和国公司法》和《公司章程》的规 定。 二、董事会会议审议情况 1．关联董事王丽丽女士、孟凡博先生回避后，以七票赞同、零票反对、零票弃权审议通过了《关于终 止对外投资暨关联交易的议案》； 本议案已分别经公司第八届董事会战略委员会2025年第三次会议、第八届董事 ...

格隆汇9月26日丨神州数码(000034.SZ)公布，公司下属子公司北京神州数码有限公司拟与中国南方航空 股份有限公司（简称"南方航空"）签订《数据库软件采购（2024）采购合同》，销售数据库软件，合同 金额3,995万元。公司董事长郭为先生为公司控股股东和实际控制人，其同时在南方航空任独立非执行 董事，根据《深圳证券交易所股票上市规则》的规定，南方航空为本公司的关联法人，本次交易构成关 联交易。 ...

招股书显示，创达新材成立于2003年，主营业务是高性能热固性复合材料的研发、生产和销售。公司的主要产品包括环氧 模塑料、液态环氧封装料、有机硅胶、酚醛模塑料和导电银胶等电子封装材料。 根据申请文件，无锡绍惠贸易有限责任公司主营业务为化工产品及原料的贸易，曾为创达新材全资子公司，2023年11月， 创达新材向无锡妙阳转让了其15.01%的股权，持股比例降至4.99%，使其成为参股公司。 创达新材同时存在向无锡绍惠及其关联方上海晟一等的购销交易，报告期内，创达新材向无锡绍惠及采购金额分别为 508.76万元、614.55万元、846.45万元，2024年无锡绍惠成为创达新材第五大供应商。 北交所请创达新材说明无锡绍惠设立的背景，结合无锡绍惠的历史股东、主营业务、经营情况等，说明创达新材历次处置 无锡绍惠股权的对手方、原因及合理性，注册地址、办公地址、主要生产经营地址重合的原因及合理性，创达新材是否真 实处置了无锡绍惠的股权，是否仍实际控制无锡绍惠。 瑞财经 王敏 9月25日，无锡创达新材料股份有限公司（以下简称"创达新材"）及申万宏源承销保荐发布关于第一轮问询的 回复，涉及关联交易必要性与合理性等。 说明历次股权 ...

Core Viewpoint - The acquisition of a 30% stake in Hubei Yongyi by Aiyingshi aims to enhance the company's self-owned brand business and optimize product offerings, despite the financial challenges posed by Hubei Yongyi's current losses [1][2][3]. Group 1: Acquisition Details - Aiyingshi plans to purchase 30% of Hubei Yongyi for 19 million yuan, using its own funds, which will allow Aiyingshi to hold a total of 30% of Hubei Yongyi after the transaction [1]. - Hubei Yongyi, established in February 2015, specializes in hygiene products, including baby and adult diapers, and has several proprietary brands [1][3]. - The transaction is classified as a related party transaction since the seller, Shi Qiong, is the actual controller and chairman of Aiyingshi [3]. Group 2: Financial Performance - Hubei Yongyi reported a net loss of 1.0272 million yuan in 2024, which worsened to a loss of 3.5605 million yuan in the first half of 2025, indicating a significant decline in profitability [2][3]. - Aiyingshi's revenue for the first half of 2025 was 1.835 billion yuan, reflecting an 8.31% year-on-year increase, while net profit attributable to shareholders rose by 10.17% to 47 million yuan [2]. Group 3: Strategic Implications - The acquisition is expected to facilitate supply chain vertical integration, reduce procurement costs, and enhance market competitiveness for Aiyingshi [2][5]. - The deal is seen as a strategic move to secure upstream supply and increase the proportion of self-owned brands, which is crucial for improving gross margins and integrating the supply chain [5]. - The transaction price of 19 million yuan is considered reasonable given Hubei Yongyi's current financial state, with the valuation of the 30% stake being 65.3685 million yuan [4][5].

本次调整后，美智二期普通合伙人仍为美的资本，有限合伙人调整为美的美善、科创母基金、悦城邦、 邓伟其、伊之密、开发区科创母公司、李伟文及公司。其中美的资本及美的美善与公司系公司关联方， 本次事项构成与关联方共同投资及放弃优先认购权的关联交易。 本次增资12,548万元，其中，美的创业投资管理有限公司(以下简称"美的资本")增资325万元，广东美的 美善科技投资合伙企业(有限合伙)(以下简称"美的美善")增资3,766万元、广州科技成果产业化引导基金 合伙企业(有限合伙)(以下简称"科创母基金")增资2,457万元、佛山市顺德区悦城邦投资有限公司(以下简 称"悦城邦")增资6,000万元、邓伟其减资1,000万元、新增合伙人李伟文出资额1,000万元，伊之密股份有 限公司(以下简称"伊之密")、广州开发区科创母基金管理有限公司(以下简称"开发区科创母公司")及公 司的出资额度不变。公司拟放弃本次增资的优先认购权。 格隆汇9月26日丨会通股份(688219.SH)公布，美智二期(广东)创业投资合伙企业(有限合伙)(以下简称"美 智二期")合伙人拟调整出资额并引入新合伙人，本次调整后美智二期总投资额为49,000万元 ...

Core Viewpoint - The recent announcement by *ST Lvkang to "sell three wholly-owned subsidiaries for 0 yuan" has raised concerns from the Shenzhen Stock Exchange, highlighting the company's deepening operational crisis and strategic missteps [1][2]. Group 1: Asset Acquisition and Disposal - In January 2023, *ST Lvkang acquired Lvkang Yushan for 95 million yuan, viewing it as a key step into the photovoltaic film sector. However, less than two years later, this and two other subsidiaries were sold for 0 yuan to an affiliated party, Jiangxi Raoxin New Energy [2]. - The acquisition of Lvkang Yushan was based on a valuation of 95.7 million yuan, despite its book value being only 1.6035 million yuan, indicating a nearly 60-fold premium. The company claimed it had a technological advantage and stable orders as a core supplier for JinkoSolar [2]. - Following the acquisition, Lvkang Yushan reported continuous losses, with a projected loss of 203 million yuan in 2024, leading to a total book value of the three subsidiaries being negative 100 million yuan [2][3]. Group 2: Financial Performance and Strategic Failures - Originally focused on veterinary medicine, *ST Lvkang's performance declined, prompting a high-profile pivot to the photovoltaic film sector in 2023, including a 290 million yuan investment in a new production project [3]. - The company's net profit attributable to shareholders showed a downward trend with losses of 122 million yuan in 2022, 222 million yuan in 2023, and an expected 445 million yuan in 2024, totaling nearly 700 million yuan in losses [3]. - The rapid expansion in the photovoltaic sector led to oversupply, and the company failed to adapt, resulting in negative net assets and a warning of delisting risk [3]. Group 3: Related Party Transactions and Shareholder Impact - The 0 yuan transaction with Raoxin New Energy, controlled by the company's major shareholder, has been interpreted as an asset stripping maneuver to offload burdens and avoid delisting [4]. - Although the company claims that the transaction does not harm minority shareholders, the transfer of significant loss-making assets raises questions about whether it genuinely resolves underlying issues or merely conceals risks off-balance sheet [4]. Group 4: Future Challenges and Lessons - Even after shedding photovoltaic assets, *ST Lvkang faces ongoing challenges, including a shrinking core business, insufficient profitability, and tight cash flow [5]. - The company has warned of risks related to changes in its main business structure and potential underperformance in profitability following the transaction [5]. - The case of *ST Lvkang serves as a cautionary tale for companies considering cross-industry ventures, emphasizing the need for careful assessment of industry cycles and internal capabilities to avoid resource misallocation and financial crises [5].

【环球网财经综合报道】百奥赛图（北京）医药科技股份有限公司作为聚焦基因编辑与抗体药物研发的生物医药企业，目前正在申请上市，然而结合公开资 料与前期披露信息，公司在人员变动、关联交易、信息披露、研发投入等方面存在争议。 人员锐减与研发缩水：经营可持续性遭质疑 百奥赛图研发团队规模的大幅收缩，成为市场质疑其经营稳定性的首要问题。公开数据显示，2022年8月，公司三个服务中心约有904名研发人员从事临床前 研究服务，涵盖基因编辑、临床前药理药效评估、模式动物销售、抗体开发等核心领域。但截至2024年末，公司研发人员仅剩337人，2年半时间内减少 63%，人员流失幅度远超行业平均水平。 从整体员工规模来看，公司同样呈现明显缩减趋势。2021年末至2024年末，员工总数从1392人降至1095人，其中2022年至2023年员工数量从1334人骤减至 1047人，一年之内减少287人。有观点认为，在生物医药行业高度依赖研发人才的背景下，如此大规模的人员流失，不仅可能导致核心技术传承断裂、研发 项目推进受阻，更引发市场对公司经营战略调整、业务收缩或资金压力的猜测，其经营可持续性亟待进一步说明。 | 专业类别 | 人数 | ...

Core Viewpoint - The company Zhongman Petroleum plans to acquire a 49% stake in Rising Energy International Middle East FZCO for approximately 560 million RMB, aiming for full ownership of the company and its oil and gas assets in Kazakhstan [1][4][3]. Group 1: Acquisition Details - Zhongman Petroleum's wholly-owned subsidiary, Zhongman Haibay, will purchase the 49% stake from China Rising Energy International (Cayman) Co., Limited for 79.3183 million USD, equivalent to about 560 million RMB [4][6]. - Prior to the acquisition, Zhongman Haibay already held a 51% stake in Rising Energy, making it the controlling shareholder [6]. - The transaction is classified as a related party transaction due to the ownership structure, with the ultimate controlling party being Li Chundi, the actual controller of Zhongman Petroleum [2][7]. Group 2: Financial Implications - The independent directors of Zhongman Petroleum believe that the acquisition will enhance the company's oil and gas resource reserves, increase production, and ultimately improve financial performance [8]. - The valuation report indicates that the total equity value of Rising Energy is approximately 1.149 billion RMB, with a book value of 579 million RMB, resulting in a valuation increase of 570 million RMB, representing a 98.54% premium [10][11]. - The increase in value is primarily attributed to long-term equity investments, which saw a valuation rise from 392 million RMB to 963 million RMB, reflecting a 145.41% increase [11]. Group 3: Asset Overview - The project in question, the Jange oil and gas field, is located in southwestern Kazakhstan and is characterized as a medium-sized oil and gas field with developed surrounding infrastructure [12]. - According to a third-party assessment, the Jange oil field has a 2P (Proven and Probable) geological oil reserve of 64.41 million tons, with an economically recoverable reserve of 5.9753 million tons [12].

新华财经北京9月25日电 大智慧发布重组报告书草案，湘财股份拟换股吸收合并大智慧。截至换股实施 股权登记日，湘财股份持有的大智慧股份以及新湖集团持有的大智慧股份将直接予以注销，不参与换 股，湘财股份亦不就该等股份支付对价。本次吸收合并后，大智慧将终止上市，并注销法人资格；湘财 股份作为存续公司将承继及承接大智慧的全部资产、负债、业务、人员、合同、资质及其他一切权利与 义务。湘财股份的A股换股价格为7.51元／股，大智慧的A股换股价格为9.53元／股。 公告称，本次换股吸收合并中，按照换股比例1:1.27计算，湘财股份拟发行的股份数量合计为22.82亿 股。换股实施后，湘财股份的总股本拟增至51.41亿股。本次募集配套资金总额不超过80亿元，拟用于 金融大模型与证券数字化建设项目、大数据工程及服务网络建设项目、财富管理一体化项目、国际化金 融科技项目、补充流动资金及偿还债务等用途。本次交易构成重大资产重组及关联交易。 编辑：王媛媛 ...

大智慧发布重组报告书草案，本次采用湘财股份换股吸收合并大智慧的方式，即湘财股份将向换股对象 发行A股股份，作为向其支付吸收合并的对价。湘财股份的A股换股价格为7.51元/股，大智慧的A股换 股价格为9.53元/股。本次交易构成重大资产重组及关联交易。 ...